CymaBay puts PBC Seladelpar Clinical Trials on hold
Seladelpar, a drug developed for PBC patients, has shown positive results in Phase 2 studies- normalizing ALP levels, while not associated with itching. In November with FDA breakthrough therapy
Elafibranor shows positive preliminary results
Elafibranor, phase 2 trial has shown positive preliminary results in helping those PBC patients who do not respond to UDCA (Urso). In addition, Elafibranor has recently been granted “Breakthrough Therapy
Canadian Clinical Trials
PBC patients across Canada can get involved in a number of Clinical Trials. Learn more about all of the clinical trials now underway and read details about who qualifies for
Linerixibat (GSK2330672) granted Orphan Status
Linerixibat (GSK2330672), a drug that is being developed for PBC patients who experience itchiness, has recently been granted “orphan” status by the FDA. This is wonderful news for patients who
Phase 3 now enrolling
As a result of extremely promising results of Phase 2 trials, Cymabay Therapeutics is now enrolling patients in a Phase 3 study for Seladelpar. This is a 52 week triple
Promising Interim Results for Phase 2 Trial
Genkyotex “published interim efficacy results today, GKT831 met both it’s primary and secondary endpoints in the Phase II PBC trial! A big thank you to the patients who participate in the
Phase 2 trial for PBC non-bile acid FXR agonist cancelled
Novartis has cancelled its phase II trial for a non-bile acid FXR agonist in patients with PBC.
Proof of Concept clinical trial – Australia & New Zealand
More exciting news for PBC patients and their families. Arena Pharmaceutical is beginning a proof of concept clinical trial in Australia and New Zealand for Etrasimod. Read more. Now Enrolling Patients in Phase 2 study
Phase 2 trial is now enrolling patients in 50 centers involving 102 patients worldwide. This is a 24 week long study involving 8 clinic visits. Principal Investigators in Canada: Dr.